Pneumococcal Vaccines
Conditions
Keywords
Pneumonia, Pneumococcal Infection, 31-Valent PCV
Brief summary
The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.
Interventions
BIOLOGICAL31-valent pneumococcal conjugate vaccine
0.5 mL of VAX-31 will be administered into the deltoid muscle
BIOLOGICALPCV20
0.5 mL of the 20-valent pneumococcal conjugate vaccine will be administered into the deltoid muscle
Sponsors
Vaxcyte, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Male or female ≥50 years of age (inclusive) at the time of randomization into the study. * Previous receipt of a licensed pneumococcal vaccine or combination of licensed vaccines, with most recent vaccination ≥1 year prior to randomization; the exception is PCV21, which may have been received ≥6 months prior to randomization (confirmed). * Able and willing to complete the informed consent process. * Available for clinical follow-up through the last study visit. * In good general health or with stable underlying chronic condition(s), as determined by medical history, oral temperature, physical examination, and clinical judgment of the Investigator (ongoing chronic conditions must be documented as stable per Investigator). * Willing to have blood samples collected and used for research purposes. * Able to provide proof of identity to the satisfaction of the site personnel completing the enrollment process. * Female participants of childbearing potential, defined as premenopausal females capable of becoming pregnant, must have a negative urine pregnancy test immediately prior to randomization and agree to use acceptable contraception. Male subjects with partners of childbearing potential must agree to practice an acceptable contraception method. * Able to access and use a device connected to Wi-Fi or cellular network for completion of an electronic diary (eDiary).
Exclusion criteria
* Previous invasive pneumococcal disease (IPD) or pneumococcal pneumonia (either confirmed or self-reported) at any age. * Previous receipt of an investigational pneumococcal vaccine at any age. * Receipt of any investigational product within 30 days prior to Day 1, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study. * Receipt of any live vaccine within 30 days prior to Day 1, or receipt of any non-live (including inactivated) vaccine within 14 days prior to Day 1. * Body temperature \>38.0°C (\>100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescreened). * Current diagnosis of human immunodeficiency virus, Hepatitis B, or Hepatitis C. * History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any previous vaccination. * Individual who is pregnant, breastfeeding, or planning to become pregnant during study participation. * Has a known or suspected immunocompromising condition, including, but not limited to, leukemia, lymphoma, chronic renal failure, or congenital or acquired immunodeficiency. * Bleeding disorder diagnosed by a doctor (e.g., factor deficiency, coagulopathy, or platelet disorder requiring special precautions) resulting in clinically significant bruising or bleeding difficulties with IM injections or blood draws. * Receipt of blood or blood product (including polyclonal intravenous immunoglobulin) within 60 days prior to enrollment into the study. * Is currently receiving immunosuppressive or immune-modifying therapy, including systemic corticosteroids (this includes ≥3 months of prednisone equivalent from 5 to ≤10 mg/day and ≥2 weeks of prednisone equivalent \>10 mg/day). * Received any part of a ≥14-day course of systemic corticosteroids (prednisone equivalent \>10 mg/day) within 14 days of study vaccination • History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. * Any medical, psychiatric, or social condition that in the judgment of the Investigator is a contraindication to protocol participation or impairs a subject's ability to give informed consent. * Employee of, or first-degree relative of, any person employed by the Sponsor, the contract research organization (CRO), the Investigator, site personnel, or site
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serotype-specific OPA geometric mean titers (GMT) | 1 month after VAX-31 vaccination |
| Serotype-specific OPA geometric mean fold rise (GMFR) from baseline | 1 month after VAX-31 vaccination |
| Percentage of subjects reporting solicited local adverse events (AE) (redness, swelling, and pain at injection site) | up to 7 days after vaccination |
| Percentage of subjects reporting solicited systemic AE (fever, headache, fatigue, muscle pain, and joint pain) | up to 7 days after vaccination |
| Percentage of subjects reporting unsolicited AE | up to 31 days after vaccination |
| Percentage of subjects reporting new onset of chronic illness (NOCI), medically attended AE (MAAE), and serious adverse events (SAE) | up to 6 months after vaccination |
Secondary
| Measure | Time frame |
|---|---|
| Serotype-specific IgG geometric mean concentration (GMC) | 1 month after VAX-31 vaccination |
| Serotype-specific IgG geometric mean fold-rise (GMFR) from baseline | 1 month after VAX-31 vaccination |
Countries
United States
Outcome results
None listed